These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Naumann SC; Roos WP; Jöst E; Belohlavek C; Lennerz V; Schmidt CW; Christmann M; Kaina B Br J Cancer; 2009 Jan; 100(2):322-33. PubMed ID: 19127257 [TBL] [Abstract][Full Text] [Related]
24. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821 [TBL] [Abstract][Full Text] [Related]
25. Cedrol, a Sesquiterpene Alcohol, Enhances the Anticancer Efficacy of Temozolomide in Attenuating Drug Resistance via Regulation of the DNA Damage Response and MGMT Expression. Chang KF; Huang XF; Chang JT; Huang YC; Lo WS; Hsiao CY; Tsai NM J Nat Prod; 2020 Oct; 83(10):3021-3029. PubMed ID: 32960603 [TBL] [Abstract][Full Text] [Related]
26. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O Jin L; Kiang KM; Cheng SY; Leung GK Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658 [TBL] [Abstract][Full Text] [Related]
27. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma. Struve N; Binder ZA; Stead LF; Brend T; Bagley SJ; Faulkner C; Ott L; Müller-Goebel J; Weik AS; Hoffer K; Krug L; Rieckmann T; Bußmann L; Henze M; Morrissette JJD; Kurian KM; Schüller U; Petersen C; Rothkamm K; O Rourke DM; Short SC; Kriegs M Oncogene; 2020 Apr; 39(15):3041-3055. PubMed ID: 32066879 [TBL] [Abstract][Full Text] [Related]
28. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061 [TBL] [Abstract][Full Text] [Related]
29. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123 [TBL] [Abstract][Full Text] [Related]
30. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines. Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465 [TBL] [Abstract][Full Text] [Related]
32. miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase. Chen H; Li X; Li W; Zheng H J Transl Med; 2015 Feb; 13():69. PubMed ID: 25890369 [TBL] [Abstract][Full Text] [Related]
33. Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma. Tezcan G; Tunca B; Demirci H; Bekar A; Taskapilioglu MO; Kocaeli H; Egeli U; Cecener G; Tolunay S; Vatan O Nutr Cancer; 2017; 69(6):873-880. PubMed ID: 28718668 [TBL] [Abstract][Full Text] [Related]
34. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597 [TBL] [Abstract][Full Text] [Related]
35. Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line. Yi GZ; Liu YW; Xiang W; Wang H; Chen ZY; Xie SD; Qi ST J Neurol Sci; 2016 Aug; 367():101-6. PubMed ID: 27423571 [TBL] [Abstract][Full Text] [Related]
36. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
37. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335 [TBL] [Abstract][Full Text] [Related]
38. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways. Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789 [TBL] [Abstract][Full Text] [Related]
39. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma. Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H J Neurosurg; 2021 Mar; 134(3):701-710. PubMed ID: 32168477 [TBL] [Abstract][Full Text] [Related]
40. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells. Yang B; Ma YB; Chu SH Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]